C-ENBINiagen Bioscinece (was ChromaDex)
NAD+ restoration, nicotinamide riboside, healthy aging
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ENBI
C-ENBIC-ENBINAD+ restoration, nicotinamide riboside, healthy aging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this study is to learn about the safety of Niagen®Plus, an injectable form of nicotinamide riboside (NR), and to see how it affects levels of NAD+ in the blood. Niagen®Plus will be given either by subcutaneous (under the skin) or intramuscular (into the muscle) injection at two dose levels (50 mg or 100 mg). The main questions this study aims to answer are: Is Niagen®Plus safe and well-tolerated when given by injection several times over 100 days? How do NAD+ levels in blood change after repeated doses of Niagen®Plus? What are participants' and clinicians' experiences with the injections? Researchers will also look at changes in fatigue, sleep, quality of life, inflammation markers, mitochondrial efficiency, and perceived skin appearance. Participants will: Receive three injections in clinic on Days 1-3, followed by a Day 10 follow-up visit Self-inject Niagen®Plus at home three times per week from Days 10-100 Return to the clinic on Days 40 and 100 for safety and laboratory testing Complete short surveys about fatigue, sleep, and overall well-being throughout the study The study will include 40 generally healthy adults and will last about 100 days per participant.
The sponsor of this study is ChromaDex, Inc. This is a double-blind, randomized, crossover study to investigate the effects of 300 mg/d and 1000 mg/d TRU NIAGEN (nicotinamide riboside) compared to a placebo control on cognitive function, mood and sleep in men and women over 55 years of age. The trial is managed by Midwest Center for Metabolic and Cardiovascular Research.
%PDF-1.3 %��������� 3 0 obj > stream x��ݖ�ƕ����$�g�$x�j�%���ԙ�33��b+�Ԏm�� ?u����w�ߊ{�?���O����随�������v��.�US��z�]o���}q��h�7ؔ��f����]�/�]^VEY\�����Iq�������vW=].��eU\^ςT[��p��[�*�&���W���j�uƳ'.�-�J\�7�����uz���j �⿊��~�ۓ�,��=?)� ۓ�ٶ���o���SD�Ž���˯���fS�˪� c�����PR�� F�G�e�ũ+�\��_�l�b��!Yx�m�Zlj�xݑ.G2Y ���)���,u�uG� ^DX�7f6+t��W��� ~��]4|�^b��ڔ�����?�55�W�M�.������ ��H���rQ�U�v�l .\?�q��{����7?������Ƿ q��!{|w���O�.��?4s�v� �xc ��z��Ů�I�����6恮bXB�/��'|�(y8~�vQ��.��.��.c��7 ����$���\��KqEXɂ��Ɓ��!ֵ#v����\�aH ?m]f0;�K�w�2`�QY�q�q>ʮlH`ҳL��|q�n� �X�,R nj�� ek
Cenna Biosciences Selected for NIH Support at BIO Convention | Nazneen Dewji, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i … uture of the Baltimore biotech ecosystem. These funds from the Build Our Future Grant will be used to scale the CLIA Catalyst program at our recently opened incubator, Blackbird BioHub. CLIA Catalyst is a shared CLIA laboratory platform conceived and implemented by Eric Van Gieson , Neil "Herm" Hermansen , and colleagues at EPOCH Epigenetics, one of Blackbird BioHub’s anchor residents. The CLIA Catalyst Facility is designed to serve as a critical bridge for emerging Maryland … al testing, significantly shortening the time to deploy a diagnostic test. This award reflects a shared commitment to accelerating technologies and strengthening Baltimore’s position as a growing biotech hub. We’re thankful to have the Maryland Department of Commerce and EPOCH Epigenetics as partners in building infrastructure that helps translate breakthrough science into patient impact faster. https://lnkd.in/eE7ig4vU https://lnkd.in/eXmSUjtq 110 4 Comments Like Comment Sha … ndings at Probiota Americas and accepted the Scientific Frontiers 2026 Industry award on behalf of AG1 and our internal team of scientists Erick W., Ralph Esposito ND, LAc Jeremy Townsend PhD for this research. This award recognizes our research advancing probiotic cell counting with digital PCR (dPCR), a DNA-based method that ensures we're able to measure probiotic potency with greater precision than ever before. This work was made possible through partnership with two indus … ndings at Probiota Americas and accepted the Scientific Frontiers 2026 Industry award on behalf of AG1 and our internal team of scientists Erick W., Ralph Esposito ND, LAc Jeremy Townsend PhD for this research. This award recognizes our research advancing probiotic cell counting with digital PCR (dPCR), a DNA-based method that ensures we're able
Exhibitors Dave Asprey's BEYOND Biohacking Conference Log in Language Resource center Contact app support Legal Home Exclusive Offers Event Agenda Speakers Exhibitors Download the Maps Help Desk & Resources Filters Exhibitor Level Title Sponsor Presenting Sponsor Sponsors VIP Lounge & Platinum Exhibitor Dance Party Sponsor Hotel Keycard Sponsor Platinum Exhibitor Gold Exhibitor Silver Exhibitor Marketing & Swag Sponsor Topics AI & FUTURE HEALTH TECHNOLOGIES BIOHACKING CONSCIOUSNESS & LONGEVITY BRAIN HEALTH BUSINESS CELLULAR HEALTH CONSCIOUSNESS DETOXIFICATION PROTOCOLS
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Niagen Bioscience builds U.S. supply chain for resilience | Niagen Bioscience posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj > stream ����JFIF��(ICC_PROFILEmntrRGB XYZ acsp���- desc�trXYZdgXYZxbXYZ�rTRC�(gTRC�(bTRC�(wtpt�cprt� �U����=��3�K�$b�ZP��9i5�����r��G�=�s�?(�GU���|J��2{L+�Nٿc�^0j)��Ř���5�i��#z�d�ls�h��r�& ���i�:�}����r��Eo��Ĭ��a�������̇�}N}U�&�$�� "g�桖�{͡�����Y�F�mr_,ƣ6=�;��'�b�99 �� ���^aG_]��]����M�4v�KZ>�C��Y�j'��a�]?�!�? ��� M�j�u�>x� O Jz�ғ��5q���^+9�[^�_Ӈ w�n���\\��9�s3�Z���+ZұJV+X� �i�G������krZ(b_��f>Ux��K3[�ktq9&�� v�N� 8W��� � H�X�1֓gkrD�HihqLo�@ 4�;�(�,�i�w�Q�Y.R��g���T�������H�ߺZ�-{]����{9f5[�����h3ۧ��g … am endobj 224 0 obj > >> endobj 225 0 obj > >> endobj 226 0 obj > stream EO.Pdf application/pdf EO.Pdf 19.1.40.0 endstream endobj 227 0 obj > stream HLinomntrRGB XYZ � 1acspMSFTIEC sRGB���-HP cprtP3desc�lwtpt�bkptrXYZgXYZ,bXYZ@dmndTpdmdd��vuedL�view�$lumi�meas $tech0 rTRC ELRY`gnu|���������������� &/8AKT]gqz������������ !-8COZfr~���������� -;HUcq~������
ChromaDex Receives Strategic Investment From DSM Venturing Newsletter subscription Industry news Industry news All news Business New product development Nutrition & health Packaging & processing Personal care & cosmetics Policy & regulation Research & science Tech & innovation Trending now Sweet success: Cargill touts integrated formulation approaches to balance sweetness and nutrition Kraft Heinz unveils plans to reorganize into three new regions Manus unveils fermentation-based monk fruit sweetener for scalable sugar reduction Category news Category news Alcoholic bev
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj > stream ����JFIF��(ICC_PROFILEmntrRGB XYZ acsp���- desc�trXYZdgXYZxbXYZ�rTRC�(gTRC�(bTRC�(wtpt�cprt� �U����=��3�K�$b�ZP��9i5�����r��G�=�s�?(�GU���|J��2{L+�Nٿc�^0j)��Ř���5�i��#z�d�ls�h��r�& ���i�:�}����r��Eo��Ĭ��a�������̇�}N}U�&�$�� "g�桖�{͡�����Y�F�mr_,ƣ6=�;��'�b�99 �� ���^aG_]��]����M�4v�KZ>�C��Y�j'��a�]?�!�? ��� M�j�u�>x� O Jz�ғ��5q���^+9�[^�_Ӈ w�n���\\��9�s3�Z���+ZұJV+X� �i�G������krZ(b_��f>Ux��K3[�ktq9&�� v�N� 8W��� � H�X�1֓gkrD�HihqLo�@ 4�;�(�,�i�w�Q�Y.R��g���T�������H�ߺZ�-{]����{9f5[�����h3ۧ��g … ;�d� ����"��~�Y > >> endobj 252 0 obj > >> endobj 253 0 obj > stream EO.Pdf application/pdf EO.Pdf 19.1.40.0 endstream endobj 254 0 obj > stream HLinomntrRGB XYZ � 1acspMSFTIEC sRGB���-HP cprtP3desc�lwtpt�bkptrXYZgXYZ,bXYZ@dmndTpdmdd��vuedL�view�$lumi�meas $tech0 rTRC ELRY`gnu|���������������� &/8AKT]gqz������������ !-8COZfr~���������� -;HUcq~������
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Niagen Bioscience Sponsors Inaugural NAD for Health Conference in Copenhagen Download About Us Support العربية Invest Products Pricing Academy Free Stocks Hot Trading Sahm ID My Account Log Out Sign up / Log in Open Account Open Account Home News Detail Niagen Bioscience Sponsors Inaugural NAD for Health Conference in Copenhagen Reuters 09/02 16:34 العربية Like Facebook Twitter Email Link Share Facebook Twitter Email Link Cancel Niagen Bioscience, Inc. Niagen Bioscience, Inc. NAGE 0.00 0.00% Niagen Bioscience Inc. (NASDAQ: NAGE), a global authority on NAD+ science focused on healthy aging, wil
ChromaDex Announces Strategic Investment Led by Mr. Li --> Accessibility: Skip TopNav ChromaDex Announces Strategic Investment Led by Mr. Li Ka-shing April 27, 2017 06:30 ET | Source: ChromaDex, Inc. ChromaDex, Inc. IRVINE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has entered into a securities purchase agreement for the sal
Niagen Bioscience - ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results Skip to main content Overview News Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Board of Directors Committee Composition Resources Investor FAQs Investor Email Alerts Investor Contacts Investor Docs Market Surveillance News Details View All News ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results March 4, 2025 Download (opens in new window) Full year net sales of $ … ddress regulatory considerations and advance its Investigational New Drug (IND) application for the treatment of Ataxia Telangiectasia (AT), a rare and progressive childhood disorder impacting neurological and immune function. “ChromaDex proudly delivered a record breaking $29.1 million in net sales for the fourth quarter of 2024, up 37% from the prior year quarter, with $7.2 million in net income. This contributed to full year net sales of $99.6 million, a 19% increase year- … Reports SEC Filings End of Day Stock Quote Events & Presentations Submit Unsubscribe X Linkedin Instagram Facebook YouTube © 2026 Niagen Bioscience - All rights reserved Powered By Q4 Inc. 5.180.2.5 (opens in new window) Patents opens in new window | Privacy Policy opens in new window | California Consumer Privacy Statement opens in new window | Consumer Health Data Privacy opens in new window | Terms of Use opens in new window | Site Map opens in new window
ChromaDex, Inc. Announces Strategic Investment Led By Mr. Li Ka-shing - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach ChromaDex, Inc. Announces Strategic Investment Led By Mr. Li Ka-shing April 28, 2017 | 4 min read Twitter LinkedIn Facebook Email Print IRVINE, Calif., April 27, 2017 -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based soluti … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Niagen Bioscience - Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen Skip to main content Overview News Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Board of Directors Committee Composition Resources Investor FAQs Investor Email Alerts Investor Contacts Investor Docs Market Surveillance News Details View All News Niagen Bioscience is the Premiere Sponsor of th … Reports SEC Filings End of Day Stock Quote Events & Presentations Submit Unsubscribe X Linkedin Instagram Facebook YouTube © 2026 Niagen Bioscience - All rights reserved Powered By Q4 Inc. 5.180.2.5 (opens in new window) Patents opens in new window | Privacy Policy opens in new window | California Consumer Privacy Statement opens in new window | Consumer Health Data Privacy opens in new window | Terms of Use opens in new window | Site Map opens in new window
Niagen Bioscience - Investor Relations Skip to main content Overview News Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Board of Directors Committee Composition Resources Investor FAQs Investor Email Alerts Investor Contacts Investor Docs Market Surveillance INVESTOR RELATIONS Corporate Overview Niagen Bioscience Inc., formerly ChromaDex, is a global bioscience company uncovering the potential of NAD+ with precision science. Led by world-renowned scientists working with global re … in cash and no outstanding borrowings. Discover our industry leadership, Nobel Prize-winning research expertise, and market-leading position in the rapidly expanding NAD+ sector. --> Download Our Corporate Fact Sheet Our Purpose We exist to improve healthspan by restoring and optimizing NAD+ levels, empowering people to live healthier and more vibrant lives as they age. Our Promise With over 25 years of innovation, Niagen Bioscience is the global leader in NAD+ research and … Reports SEC Filings End of Day Stock Quote Events & Presentations Submit Unsubscribe X Linkedin Instagram Facebook YouTube © 2026 Niagen Bioscience - All rights reserved Powered By Q4 Inc. 5.180.2.5 (opens in new window) Patents opens in new window | Privacy Policy opens in new window | California Consumer Privacy Statement opens in new window | Consumer Health Data Privacy opens in new window | Terms of Use opens in new window | Site Map opens in new window
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Niagen Bioscience - Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen® Skip to main content Overview News Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Board of Directors Committee Composition Resources Investor FAQs Investor Email Alerts Investor Contacts Investor Docs Market Surveillance News Details View All News Niagen Bioscience Secures New U.S. Patent Covering Intravenous a … Reports SEC Filings End of Day Stock Quote Events & Presentations Submit Unsubscribe X Linkedin Instagram Facebook YouTube © 2026 Niagen Bioscience - All rights reserved Powered By Q4 Inc. 5.180.2.5 (opens in new window) Patents opens in new window | Privacy Policy opens in new window | California Consumer Privacy Statement opens in new window | Consumer Health Data Privacy opens in new window | Terms of Use opens in new window | Site Map opens in new window
Niagen Bioscience Signs Patent Assignment Agreement With Queen's University Belfast — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Niagen Bioscience Signs Patent Assignment Agreement With Queen's University Belfast Niagen Bioscience Signs Patent Assignment Agreement With Queen's University Belfast 1 min read NAGE Niagen Bioscience, through subsidiary ChromaDex, signed a patent assignment with Queen's University Belfast, replacing prior joint ownership and license arrangements. Effective Dec 16 2025, the deal transfers fu
Niagen Bioscience updates patent deal with Queen’s University | NAGE 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto S
cdxc-20251218 0001386570 FALSE 0001386570 2025-12-18 2025-12-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 10900 Wilshire Blvd. Suite 600 , Los Angeles , California 90024 (Address of principal
Niagen Bioscience Inc. (Nasdaq: NAGE) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 115 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> WidePoint Named Single Awardee of the $3.1 Billion DHS CWMS 3.0 Contract (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historic
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Niagen Bioscience Inc. (Nasdaq: NAGE) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 115 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> WidePoint Named Single Awardee of the $3.1 Billion DHS CWMS 3.0 Contract (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historic
Niagen Bioscience grows 2025 net sales to $129.4M | NAGE Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Sto … eding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No • whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b- … ; our ability to develop pharmaceutical business; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions, inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, m … to develop and commercialize these proprietary ingredients ourselves as well as grant licenses to external companies for their commercialization. The following table sets forth our existing patents and those to which we have licensed rights: Patent Number Title Filling Date Issued Date Expires Licensor 8,106,184 Nicotinyl Riboside Compositions and Methods of Use 11/17/2006 1/31/2012 9/20/2027 Licensed from Cornell University 9,000,147 Nicotyl riboside compositions and methods … both to meet our projected operating plans after the next twelve months and to fund our longer-term strategic objectives. Additional capital may come from public and private equity or debt offerings, borrowings under lines of credit or other sources. These additional funds may not be available on favorable terms, or at all. There can be no assur
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB) June 15, 2022 | 6 min read Twitter LinkedIn Facebook Email Print ChromaDex Corp. (NASDAQ:CDXC) today announced that members o … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 February 9, 2026 | 3 min read Twitter LinkedIn Facebook Email Print LOS ANGELES--(BUSINESS WIRE)-- $NAGE #Biotech -- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamid … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Niagen Bioscience - Events & Presentations Skip to main content Overview News Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Board of Directors Committee Composition Resources Investor FAQs Investor Email Alerts Investor Contacts Investor Docs Market Surveillance Events & Presentations Upcoming & Recent Events Featured Presentation Archived Events Selecting a year value will change the event content Select year: Loading... Archived Presentations Selecting a year value will cha … Reports SEC Filings End of Day Stock Quote Events & Presentations Submit Unsubscribe X Linkedin Instagram Facebook YouTube © 2026 Niagen Bioscience - All rights reserved Powered By Q4 Inc. 5.180.2.5 (opens in new window) Patents opens in new window | Privacy Policy opens in new window | California Consumer Privacy Statement opens in new window | Consumer Health Data Privacy opens in new window | Terms of Use opens in new window | Site Map opens in new window
Niagen Bioscience - Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway Skip to main content Overview News Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Board of Directors Committee Composition Resources Investor FAQs Investor Email Alerts Investor Contacts Investor Docs Market Sur … Reports SEC Filings End of Day Stock Quote Events & Presentations Submit Unsubscribe X Linkedin Instagram Facebook YouTube © 2026 Niagen Bioscience - All rights reserved Powered By Q4 Inc. 5.180.2.5 (opens in new window) Patents opens in new window | Privacy Policy opens in new window | California Consumer Privacy Statement opens in new window | Consumer Health Data Privacy opens in new window | Terms of Use opens in new window | Site Map opens in new window
Niagen Bioscience (NAGE) | Trefis Niagen Bioscience (NAGE) | Trefis | Trefis All Data About Our Story Management Team Investors and Advisors Careers Contact Us Try Trefis Sign In × Try Trefis Sign In All Data About Our Story Management Team Investors and Advisors Careers Contact Us Try Trefis Sign In Tearsheet NAGE Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About NAGE Interactive Breakdown Better Bets vs. NAGE Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Comparisons - Financials - Gro … ompetitive pressures. Show less. NAGE in ETFs Weight = NAGE's share of each fund VTI 0.00% VTWO 0.01% SCHA 0.00% SCHB 0.00% Valuation & Metrics Valuation Consensus Key Metrics Op. Metrics FYE: 12/31 Forward FYE Now Historical (CYE & TTM) 2027 2026 6/25/26 2025 2024 2023 2022 Share Price $3.45 $6.36 � � � Mkt Cap ($ Mil) 275.7 507.9 - - - + Debt ($ Mil) 2.6 2.8 2.7 3.3 4.3 - Cash ($ Mil) 66.4 64.6 44.5 27.2 … e on the rapidly expanding NAD market. This includes exploring and entering new application areas such as skincare, cosmetics, food, beverages, and pharmaceuticals. The company is also optimistic about the potential for Niagen products in specific health areas like the GLP-1 market and among Parkinson's patients. The launch of a Niagen® Skincare Innovation Lab and new dermatologically tested products further illustrates this expansion. Focus on Core NAD Science and Intellectu
10-K 1 cdxc10k_dec302017.htm ANNUAL REPORT Form 10-K       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K    [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.   For the fiscal year ended December 30, 2017 or   [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to   Commission file number 001-37752   CHROMADEX CORPORATION (Exact name of Registrant as specified in its Charter)   Dela … eding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]   Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]   Indicate by … iders and products; risks in product development; inability to raise capital to fund continuing operations; changes in government regulation; the ability to complete customer transactions and capital raising transactions, and other factors (including the risks contained in Item 1A of this Form 10-K under the heading “Risk Factors”) relating to our industry, our operations and results of operations and any businesses that may be acquired by us. Should one or more … eve there is a ready market for cost-effective concentrated anthocyanins having application in dietary supplements, sports nutrition, food and beverage and skin care.   ● Spirulina Extract Immulina™.   IMMULINA™ is a spirulina extract and the predominant active compounds are Braun-type lipoproteins which are useful for improving human immune function. These lipoproteins are present at much greater levels than those found within commonly used imm … o March 2019 both to meet our projected operating plans after March 2019 and to fund our longer term strategic objectives. Additional capital may come from public and private equity or debt offerings, borrowings under lines of credit or other sources. These additional funds may not be available on favorable terms, or at all. There can be no assur
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms March 20, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Exclusively licensed from Queen’s University Belfast (QUB), this composition of matter patent, one of the most robust forms of int … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opini … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs April 8, 2025 | 5 min read Twitter LinkedIn Facebook Email Print The Company’s flagship patented nicotinamide riboside (NR) ingredient, Niagen ® , is manufactured, encapsulated, and bottled in the U.S. and is currently classified a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience Announces Participation in Upcoming May 2026 Investor Conferences - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Can … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience Announces Participation in Upcoming May 2026 Investor Conferences May 8, 2026 | 2 min read Twitter LinkedIn Facebook Email Print LOS ANGELES--(BUSINESS WIRE)-- $NAGE #Biotech -- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science June 2, 2026 | 7 min read Twitter LinkedIn Facebook Email Print The program has supported more than 300 research collaborations across leading instituti … dies. In addition, the Company recently initiated the Niagen Bioscience Trainee Grant Program , which will award three $10,000 grants to graduate students and postdoctoral trainees pursuing investigator-initiated research for this year’s focus on exercise performance, recovery, fatigue, and adaptation, reflecting the Company’s commitment to supporting the next generation of NAD+ scientists. The Niagen Research Program website also introduces an updated application and review … n Learn more about the Niagen Research Program at www.niagenbioscience.com . To apply to the program, please email [email protected] . About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Nia … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway July 9, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Collaboration builds … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Policy ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space February 22, 2023 | 5 min read Twitter LinkedIn Facebook Email Print ChromaDex Co … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Ma … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States November 11, 2022 | 4 min read Twitter LinkedIn Facebook Email Print ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, toda … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex, Inc. Release: University Researchers Show Vitamin Nicotinamide Riboside Is An Effective Tool For Managing The Negative Effects Of Obesity And Diabetes - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Dev … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development ChromaDex, Inc. Release: University Researchers Show Vitamin Nicotinamide Riboside Is An Effective Tool For Managing The Negative Effects Of Obesity And Diabetes June 1, 2016 | 5 min read Twitter LinkedIn Facebook Email Print IRVINE, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- ChromaDex … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Dea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB) January 12, 2023 | 6 min read Twitter LinkedIn Facebook Email Print ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announ … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Nobel Laureate Roger Kornberg To Chair New ChromaDex, Inc. Scientific Advisory Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Ca … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Nobel Laureate Roger Kornberg To Chair New ChromaDex, Inc. Scientific Advisory Board July 8, 2014 | 4 min read Twitter LinkedIn Facebook Email Print IRVINE, Calif. , July 8, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary in … by Kornberg, a Professor at Stanford Medical School, who was awarded the Nobel Prize in Chemistry in 2006 for his research on the molecular basis of eukaryotic transcription . Dr. Kornberg earned his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an Assistant Professor of Biological Chemistry at Harvard … ornberg , was a professor of biochemistry at Stanford and was awarded the Nobel Prize for physiology or medicine in 1959. He was among the first to investigate nicotinamide riboside more than 60 years while at the NIH. Kornberg commented, "Given my father's noteworthy early research of nicotinamide riboside, I have been following ChromaDex's progress on developing its NIAGEN nicotinamide riboside as well as the enormous amount of published research that speaks to the health b … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex, Inc. Names Additional Scientific Advisory Board Members - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business ChromaDex, Inc. Names Additional Scientific Advisory Board Members September 5, 2014 | 6 min read Twitter LinkedIn Facebook Email Print IRVINE, Calif. , Sept. 4, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC ), an innovative natural products company that provides proprietary ingredients a … ction of dietary lipids, the role of milk components in food and health and the application of metabolic assessment to personalizing diet and health. The ChromaDex SAB is chaired by Dr. Roger Kornberg , a professor at Stanford Medical School who was awarded the Nobel Prize in Chemistry in 2006 for his research on the molecular basis of eukaryotic transcription . Dr. Kornberg earned his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical ph … ornberg , was a professor of biochemistry at Stanford and was awarded the Nobel Prize for physiology or medicine in 1959. He was among the first to investigate nicotinamide riboside more than 60 years while at the NIH. The SAB's mission is to assist the ChromaDex's management team in maximizing the value of the company's portfolio of patented ingredients, primarily by advising on such matters as scientific and research focus, clinical studies, safety and regulatory, commercia … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism July 16, 2020 | 6 min read Twitter LinkedIn Facebook Email Print First-of-its-kind preclinical study shows that Niagen® resolves social deficits and anxiety-like behaviors in male mice July 16, 2020 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™) September 20, 2021 | 5 min read Twitter LinkedIn Facebook Email Print ChromaDex Corp. announced findings from recently published preclinical studies, as well … enmark, and encouraged researchers interested in researching NAD+ precursors to apply to CERP™ . Since 2013, CERP™ has accumulated more than 235 collaborative agreements representing $85 million in total research investment. The program has also resulted in numerous patent applications and licenses. Additionally, through CERP™ to date, Niagen® has been a part of more than 65 publications, including 13 peer-reviewed, clinical trial publications. The role of the NAD + (nicotina … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model July 9, 2020 | 7 min read Twitter LinkedIn Facebook Email Print Dr. Charles Brenner and a team of scientists from three US universities find that Niagen® decreases Coronavirus replication in … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID November 12, 2025 | 9 min read Twitter LinkedIn Facebook Email Print Findings show a significant increase in NAD+ levels and within-group bene … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Dru … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA) December 2, 2019 | 3 min read Twitter LinkedIn Facebook Email Print ChromaDex advances in regulatory process for its patented nicotinamide r … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developme … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) June 13, 2024 | 9 min read Twitter LinkedIn Facebook Email Print ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research an … rp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®. Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher three hours post-infusion as compared to NAD+ IV. The U.S. FDA authorized nicotinamide riboside chloride (N … global authority on nicotinamide adenine dinucleotide (NAD + ) research and its application to healthy aging, unveils Niagen+ , the first-of-its-kind pharmaceutical-grade Niagen ® (patented nicotinamide riboside chloride or NRC). Authorized by the U.S. FDA for compounding by 503B outsourcing facilities, pharmaceutical-grade intravenous (IV) and injectable NRC will be available in IV, shot, and push forms exclusively at clinics, with a prescription. ChromaDex believes it will … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex, Inc. Licenses Exclusive Patent Rights From Dartmouth College For Pharmaceutical Use Of Nicotinamide Riboside (NR) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business ChromaDex, Inc. Licenses Exclusive Patent Rights From Dartmouth College For Pharmaceutical Use Of Nicotinamide Riboside (NR) June 3, 2014 | 8 min read Twitter LinkedIn Facebook Email Print IRVINE, Calif., June 3, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural produc … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tren … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China June 10, 2022 | 9 min read Twitter LinkedIn Facebook Email Print ChromaDex Corp. a global bioscience company dedicated to healthy aging, announced a signed distribution agreement with Sinopharm X … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Deve … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder June 9, 2025 | 8 min read Twitter LinkedIn Facebook Email Print Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development F … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 March 5, 2026 | 19 min read Twitter LinkedIn Facebook Email Print Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased … ortfolio into the beauty and nutricosmetics category and reflects the continued application of NAD+ science across additional consumer health verticals. In November 2025, the Company announced results from a randomized, double-blind, placebo-controlled clinical trial evaluating Niagen® supplementation in individuals with long COVID. The study demonstrated that Niagen® supplementation increased NAD+ levels, supporting continued scientific evaluation of NAD+ restoration in popu … ; our ability to develop pharmaceutical business; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions; inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, m … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results May 7, 2026 | 17 min read Twitter LinkedIn Facebook Email Print Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million LOS A … ; our ability to develop pharmaceutical business; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions; inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, m … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bus … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board July 23, 2019 | 4 min read Twitter LinkedIn Facebook Email Print Renowned Cancer Researcher to Support Ongoing Clinical Studies to Further Demonstrate the Safety and E … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 9 0 obj > stream x�}��JA��р( -,���"�E��J��6?�M�쎛m��e�� ���Nl|m}�B�T>Bb &�L��T�= .� ��2 �T�*������R�&�K��$�~ �����M0T� pt�m�({a�Ұ���4IA\֍��.P W�_a�h� ����wS �f�wv����p>������v�S� > stream ����JFIFdd��Ducky �$�'�Ѧ�U���F�m�������w�[�� �����L_�F���� �;�$�4����p{: ��O�@} �n �����va��@ \�����t��3��Sm��Q ����tZ4�r^n`�pk�vX!`�]E����2��u֛��|AS�+ uk䷭ �����[NE�m96��/c����4*4N�� :������~=� �X����҇�'�"��^33˔ � �n�\��Ν �7f �&��t�ߛ��{.��i�W�����ߦ�� x�\���:�rG��~��� .Wl�P��"��CA�M��2P�����m��h m�Q�fɷ��;iɶ�]�y��� … �.r�� � ���4l��Urd+����V|��!���q����Ғ Mޡp��b:63w>��ޙ;=頼��A��Q[? ��']I�wg>�rfP�0{ �bpI ��k�cQY�ݑݧ$ h)�F�{e��^!N'�;���X�����פ��g�#��`� Jp�^�������B��vZS��`��]=x�� MT\�t �Nc@l�g|s�����%�ѯ5�9������ !�����f*�Щ�F!c�T-$�-V�L�ZU�!�CkG�;;h�侚�ɖj Փf�)�N��9�8t��v�.�[ \�(+5�r����퐣��8� P�'&T,>�K��GC�[Y)�9��G�ؤa�i�!���j�=A;� P�ͦ�'�F�-��{uP!�Kx�e�3lw�� ؈����?�����K�5�y�� &lh�ӛ�� I>C鹶��0���?/�&��� ��Yv�LB���S�v�$c�YMS���a� �#���FE ���f�r��ef5��^E�e�
Niagen Bioscience - American Society for Nutrition Skip to content Member Portal Search Donate About ASN History & Archives Leadership Mission & Bylaws Affiliated Organizations Contact Us Publications Journals Research from ASN Journals Meetings & Education Annual Meeting Education RX Nutrition Nutrition Science Teaching Tools Meetings Other Meetings and Professional Development Events Membership Member Benefits Membership Application Processes Research Interest Sections Scientific Councils Sustaining Partners Inclusion, Diversity, Equity, and Accessibility ASN and IUNS Advertis … rs ASN Advocacy Nutrition Research Priorities Communications ASN Science Policy Fellowship Public-Private Partnerships Resources Foundation Fellows Awards Trust in Nutrition Science ASN News Careers in Nutrition ASN Career Center Career Pathways Nutrition Programs Meet ASN Members Search for: Return to Directory Niagen Bioscience Return to Directory Niagen Bioscience Company Website Dietary Supplements About Niagen Bioscience (formerly ChromaDex Corp) is the parent company of … and third-party funded, select studies that align with business priorities may apply for funding. Some of these priorities include: The Role of NAD+ in Healthy Aging and Age-Related Disease Age-Related Declines In: Cognition Exercise Performance Quality of Life/Sleep Sensory (Vision, Hearing, Touch) Function Biological Age Women’s Health (Fertility, Menopause) Parenteral nutrition applications for nicotinamide riboside We are also interested in collaborating on opportunities … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. American Society for Nutrition 2440 Research Boulevard, Suite 430 Rockville, MD 20850 Telephone: 240-428-3650 © 2026 American Society for Nutrition. All Rights reserved. Privacy Policy We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Dihydronicotinamide riboside promotes cell-specific cytotoxicity by tipping the balance between metabolic regulation and oxidative stress | PLOS One Skip to main content Advertisement PLOS One Publish Submissions Getting Started Submission Guidelines Figures Tables Supporting Information LaTeX What We Publish Preprints Revising Your Manuscript Submit Now Calls for Papers Policies Best Practices in Research Reporting Human Subjects Research Animal Research Competing Interests Disclosure of Funding Sources Licenses and Copyright Data Availability Complementary Research Materials, Software and Co … ew Process Editor Center Guidelines for Reviewers Accepted Manuscripts Comments Submit Your Manuscript Discover a faster, simpler path to publishing in a high-quality journal. PLOS ONE promises fair, rigorous peer review, broad scope, and wide readership – a perfect fit for your research every time. Learn More Submit Now About Why Publish with PLOS ONE Journal Information Staff Editors Editorial Board Section Editors Advisory Groups Find and Read Articles Publishing Informati … plications (e.g. WO 2018102426 A1 20180607) to ChromaDex, Ltd., and 2) research grant support from Elysium Health. The funder has no role in the study design; collection, analysis, and interpretation of data; writing of the paper; and decision to submit for publication. This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests ). Introduction Nicoti … View Article PubMed/NCBI Google Scholar 35. Holton NW, Andrews JF, Gassman NR. Application of Laser Micro-irradiation for Examination of Single and Double Strand Break Repair in Mammalian Cells. J Vis Exp. 2017;(127):e56265. pmid:28930988. View Article PubMed/NCBI Google Scholar 36. Hunter SE, Jung D, Di Giulio RT, Meyer JN. The QPCR assay for analysis of mitochondrial DNA damage, repair, and relative copy number. Methods. 2010;51(4):444–51. Epub 02/01. pmid:20123023. View A
Niagen Bioscience's NR ingredient improves health in Werner syndrome patients | Niagen Bioscience posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Contin
Niagen® Practitioner | Clinically Proven NAD+ Support for Patients The #1 NAD+ supplement in the U.S.³ Learn More . Register for our Monthly Webinar. Register here . The #1 NAD+ supplement in the U.S.³ Learn More . Register for our Monthly Webinar. Register here . Skip to content Niagen® Practitioner Products Explore Our Products Shop All Products Tru Niagen Tru Niagen® 300mg Tru Niagen® 500mg Tru Niagen® 1000mg Tru Niagen® 300mg Stick Packs Tru Niagen® Immune Tru Niagen® Beauty Brochures In-Clinic Resources Learn More Discover All Benefits Monographs Tru Niagen® Monograph NRCl Monograph One-P … om the NAD+ authority trusted by physicians, athletes, researchers, and a Nobel Prize-winning biochemist. 45+ Human Clinical Studies on Niagen® NR 60+ Proprietary NR Patents 500+ Published Scientific Studies 300+ Global Research Collaborations Trusted quality, rigorously verified GRAS FDA-reviewed Generally Recognized As Safe status for Niagen®, the highest safety designation for dietary ingredients. NSF Certified for Sport® Third-party tested and certified free from banned s … ents, and indeed, a gold standard in the industry." Roger Kornberg, Ph.D. Nobel Prize Winner in Chemistry | Mrs. George A. Winzer Professor of Medicine, Stanford | Niagen Bioscience Scientific Advisory Board Chairman "Disturbances in NAD coenzymes can leave tissues unable to repair themselves, generate energy, and perform their normal homeostatic functions. In many conditions of metabolic stress, the genes that convert NR to NAD are up-regulated, which provides unique value o
Tru Niagen® | Clinically Studied NAD+ Booster for Cellular Health Prime Summer Savings: Save up to 30% for a limited time. Shop Now NAD+ skincare powered by Niagen®. Learn More . Good news: Tru Niagen now accepts HSA/FSA. Learn more . Prime Summer Savings: Save up to 30% for a limited time. Shop Now NAD+ skincare powered by Niagen®. Learn More . Good news: Tru Niagen now accepts HSA/FSA. Learn more . Skip to content Pharma-Grade Niagen HCP Pro Site Shop Explore Our Products Shop All Products Foundational Tru Niagen® 300mg Tru Niagen® 300mg Stick Packs Tru Niagen® 150mg Pro Tru Niagen Pro® 1,00 … om the NAD+ authority trusted by physicians, athletes, researchers, and a Nobel Prize-winning biochemist. 45+ Human Clinical Studies on Niagen® NR 60+ Proprietary NR Patents 500+ Published Scientific Studies 300+ Global Research Collaborations Discover the best NAD-boosting solution for you Foundational Our bestselling minimum recommended daily servings to support cellular energy and repair. Shop Now Pro Originally made for pro athletes and physicians, now available for healt … ents, and indeed, a gold standard in the industry." Roger Kornberg, Ph.D. Nobel Prize Winner in Chemistry | Mrs. George A. Winzer Professor of Medicine, Stanford | Niagen Bioscience Scientific Advisory Board Chairman "Disturbances in NAD coenzymes can leave tissues unable to repair themselves, generate energy, and perform their normal homeostatic functions. In many conditions of metabolic stress, the genes that convert NR to NAD are up-regulated, which provides unique value o
Scientific Advisory Board - NIBN --> “It is in the Negev that Jewish scientific talent and research ability shall be tested.” --> David Ben-Gurion Israel’s First Prime Minister --> GET TO KNOW NIBN --> About Us NIBN at a Glance Mission and Vision Brief History Leadership NIBN Management Board of Directors Executive Committee Scientific Advisory Board Edgar de Picciotto Science & Innovation Research Fields Research Groups Cancer Neurodegenerative Diseases Autoimmune and Metabolic Diseases Applied Biotechnology Infectious Diseases Human Genetic Disorders AgBio Ongoing Projects Projects for Comme … ebrew University of Jerusalem and recipient of the Israeli Ministry of Health’s prize, Prof. Soreq is best known for her work on the signaling of acetylcholine and its relevance in stress responses and Parkinson’s and Alzheimer’s diseases. She became an Associate Professor of molecular biology in the Department of Biological Chemistry at the Hebrew University from 1986 and served as the Head of the university’s Silberman Institute of Life Sciences (1995-2000) and Dean of its … e, nerves, and blood cells. Prof. Roger D. Kornberg Recipient of the 2006 Nobel Prize in Chemistry, Prof. Roger D. Kornberg earned his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford University in 1972. Prof. Kornberg became a postdoctoral research fellow at the Laboratory of Molecular Biology in Cambridge and then an Assistant Professor of Biological Chemistry at Harvard Medical School in 1976, before moving to h … Structural Biology at the Stanford School of Medicine in 1978. Prof. Kornberg’s prize-winning research centered on the process by which DNA is converted into RNA. Prof. Kornberg has served on the Scientific Advisory Boards of the following companies: Cocrystal Discovery, Inc. (Chairman), ChromaDex Corporation (Chairman), StemRad Ltd., and Pacific Biosciences. He has also been a Director for the following companies: OphthaliX Inc., Protalix BioTherapeutics, Can-Fite BioPharma … eutical Industries Ltd. Prof. Aaron Ciechanover, MD Recipient of the 2004 Nobel Prize in Chemistry and the 2003 Israel prize. Distinguished Research Professor in the Technion - Israel Institute of Technology. He received his M.Sc. (1971) and M.D. (1973) from the Hebrew University in Jerusalem and his PhD in biochemistry (1981) from the Technion –
ChromaDex Welcomes Business & Media Executive and Academy --> Accessibility: Skip TopNav ChromaDex Welcomes Business & Media Executive and Academy Award Winning Producer, Rob Fried, to Its Board of Directors July 13, 2015 06:30 ET | Source: ChromaDex Corporation ChromaDex Corporation IRVINE, Calif., July 13, 2015 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX: CDXC ), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced to … n, Hallmark e-cards, and Hallmark Print on Demand. Mr. Fried is also an Academy Award winning motion picture producer whose credits include Rudy, Collateral, Boondock Saints, So I Married an Axe Murderer, Godzilla , and numerous others. From December 1994 until June 1996, he was President and CEO of Savoy Pictures, a unit of Savoy Pictures Entertainment, Inc., which was sold in 1996 to Silver King Communications, which is now a part of InterActive Corp. Mr. Fried has also hel
8-K 1 cdxc8k_jan82018.htm CURRENT REPORT 8-K     UNITED STATES  SECURITIES AND EXCHANGE COMMISSION   WASHINGTON, D.C. 20549 ____________   FORM 8-K   CURRENT REPORT         PURSUANT TO SECTION 13 OR 15(d) OF THE   SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): January 8 , 2018   CHROMADEX CORPORATION   (Exact name of registrant as specified in its charter)   Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer I … n, Hallmark e-cards, and Hallmark Print on Demand. Mr. Fried is also an Academy Award winning motion picture producer whose credits include Rudy, Collateral, Boondock Saints, So I Married an Axe Murderer, Godzilla, and numerous others. From December 1994 until June 1996, he was President and Chief Executive Officer of Savoy Pictures, a unit of Savoy Pictures Entertainment, Inc., which was sold in 1996 to Silver King Communications, which is now a part of InterActive Corp. Mr.
ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Ma … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition May 21, 2020 | 4 min read Twitter LinkedIn Facebook Email Print ChromaDex Corp. announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of … visor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition and its Foundation. May 21, 2020 10:32 UTC Dr. Charles Brenner’s latest research focuses on effect of SARS-CoV-2 infection on cells’ NAD levels LOS ANGELES--( BUSINESS WIRE )-- ChromaDex Corp. (NASDAQ:CDXC) today announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advi … visor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition (ASN) and its Foundation. This award, presented by ASN and supported by the Council for Responsible Nutrition (CRN), recognizes an investigator who has contributed outstanding research in the field of bioactive compounds for human health. Dr. Brenner is one of the world’s foremost experts in nicotinamide adenine dinucleotide (NAD) research. In 2004, Dr … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
About Us - Nicotinamide Riboside | Tru Niagen® Prime Summer Savings: Save up to 30% for a limited time. Shop Now NAD+ skincare powered by Niagen®. Learn More . Good news: Tru Niagen now accepts HSA/FSA. Learn more . Prime Summer Savings: Save up to 30% for a limited time. Shop Now NAD+ skincare powered by Niagen®. Learn More . Good news: Tru Niagen now accepts HSA/FSA. Learn more . Skip to content Pharma-Grade Niagen HCP Pro Site Shop Explore Our Products Shop All Products Foundational Tru Niagen® 300mg Tru Niagen® 300mg Stick Packs Tru Niagen® 150mg Pro Tru Niagen Pro® 1,000mg Beauty Tru Niag … ard in scientific rigor, safety, quality, and transparency. Backed by one Nobel Prize winner, 45+ human clinical studies, and 500+ published scientific studies, and has been accepted by the world’s most rigorous regulatory bodies. We want to get the most out of every moment. Our purpose is to invigorate life, even through challenging times. A legacy of innovation and discovery 1999 2005 2013 2016 2020 Today 1999 A vision is born ChromaDex is founded with a bold mission: to br … he industry standard for safety, quality, and transparency. Backed by two Nobel Prize winners, 45+ clinical trials, and 500+ studies, it’s recognized by leading regulatory authorities. And we’re just getting started—Niagen Bioscience is committed to driving the future of health through innovation. Setting the gold standard in the supplement industry since 1999. Niagen Bioscience, formerly ChromaDex, represents 25 years of world-leading scientific innovation and excellence. Tr … rld-leading scientific innovation and excellence. Tru Niagen is backed by Nobel prize-winning scientists, 45+ published peer-reviewed human clinical studies and 500+ published studies. Learn More Backed by world-leading scientists Tru Niagen, powered by Niagen Bioscience, leverages 25 years of scientific excellence. Our foundation is solidified by an esteemed scientific advisory board, including Nobel Prize laureates Sir John Walker (Cambridge) and Dr. Roger Kornberg (Stanfor … g Professor of Structural Biology, Stanford University School of Medicine Nobel Prize Winner, Chemistry Dr. Rudolph Tanzi Kennedy Professor of Neurology, Harvard University Director, Genetics and Aging Research Unit, Massachusetts General Hospital Dr. Brunie H. Felding Associate Professor of Molecular Medicine, Scripps Research Institute Renowned
ChromaDex: The Transforming Benefits of Nicotinamide Riboside, Featuring Dr. Charles Brenner - LifeSci Events Skip to content ABOUT US EVENTS SERVICES TEAM CONTACT US Back to Events ChromaDex: The Transforming Benefits of Nicotinamide Riboside, Featuring Dr. Charles Brenner DATE: July 20, 2022 TIME: 12:00 AM EDT LOCATION: N/A Register About The Event The webinar will feature a presentation from Key Opinion Leader (KOL) Charles Brenner, PhD (City of Hope National Medical Center) who will discuss the latest research on Nicotinamide Riboside (NR) and its many benefits as a precursor to Nicotinami
About Us - Nicotinamide Riboside | Tru Niagen® Prime Summer Savings: Save up to 30% for a limited time. Shop Now NAD+ skincare powered by Niagen®. Learn More . Good news: Tru Niagen now accepts HSA/FSA. Learn more . Prime Summer Savings: Save up to 30% for a limited time. Shop Now NAD+ skincare powered by Niagen®. Learn More . Good news: Tru Niagen now accepts HSA/FSA. Learn more . Skip to content Pharma-Grade Niagen HCP Pro Site Shop Explore Our Products Shop All Products Foundational Tru Niagen® 300mg Tru Niagen® 300mg Stick Packs Tru Niagen® 150mg Pro Tru Niagen Pro® 1,000mg Beauty Tru Niag … ard in scientific rigor, safety, quality, and transparency. Backed by one Nobel Prize winner, 45+ human clinical studies, and 500+ published scientific studies, and has been accepted by the world’s most rigorous regulatory bodies. We want to get the most out of every moment. Our purpose is to invigorate life, even through challenging times. A legacy of innovation and discovery 1999 2005 2013 2016 2020 Today 1999 A vision is born ChromaDex is founded with a bold mission: to br … he industry standard for safety, quality, and transparency. Backed by two Nobel Prize winners, 45+ clinical trials, and 500+ studies, it’s recognized by leading regulatory authorities. And we’re just getting started—Niagen Bioscience is committed to driving the future of health through innovation. Setting the gold standard in the supplement industry since 1999. Niagen Bioscience, formerly ChromaDex, represents 25 years of world-leading scientific innovation and excellence. Tr … rld-leading scientific innovation and excellence. Tru Niagen is backed by Nobel prize-winning scientists, 45+ published peer-reviewed human clinical studies and 500+ published studies. Learn More Backed by world-leading scientists Tru Niagen, powered by Niagen Bioscience, leverages 25 years of scientific excellence. Our foundation is solidified by an esteemed scientific advisory board, including Nobel Prize laureates Sir John Walker (Cambridge) and Dr. Roger Kornberg (Stanfor … g Professor of Structural Biology, Stanford University School of Medicine Nobel Prize Winner, Chemistry Dr. Rudolph Tanzi Kennedy Professor of Neurology, Harvard University Director, Genetics and Aging Research Unit, Massachusetts General Hospital Dr. Brunie H. Felding Associate Professor of Molecular Medicine, Scripps Research Institute Renowned
Meet Dr. Charles Brenner: A leading pioneer in NAD+ science and Chief Scientific Advisor on the Niagen Bioscience Scientific Advisory Board. As the Alfred E. Mann Family Foundation Chair in Diabetes… | Niagen Bioscience LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choice
Chromadex - Roth Conference Attendee - B2i Digital Marketing FEATURED CONFERENCES VIEW ALL FEATURED CONFERENCES Upcoming In-Person Conferences ROTH 5th Annual Healthcare Opportunities Conference NIBA 153rd Investment Conference ROTH 13th Annual Solar & Storage Symposium at RE+ ROTH 15th Annual Technology Conference ROTH 15th Annual Deer Valley Event ROTH 39th Annual Conference Upcoming Virtual Conferences Virtual Investor Conferences Life Sciences Investor Forum Virtual Investor Conferences Global Technology Investor Conference Virtual Investor Conferences Precious Metals & Critical Mi … ried is the Chief Executive Officer (CEO) of ChromaDex. Mr. Fried is an Academy Award and Emmy Award winning motion picture producer. He has held senior roles at entertainment companies Savoy Pictures (CEO), Columbia Pictures (Executive Vice President) and Fried Films (founder, CEO). He has also founded and served as CEO of internet companies Feeln (now Hallmark Movies Now), WHN (a leading e-commerce service provider), and Healthspan Research (now part of Chr
424B5 1 cdxprossupp_feb12012.htm PROSPECTUS SUPPLEMENT cdxprossupp_feb12012.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333- 176636       PROSPECTUS SUPPLEMENT   DATED FEBRUARY 1 , 2012   (To the Prospectus dated October 19, 2011) Up to $8,000,000 of Shares in Common Stock ChromaDex Corporation     We are offering up to an aggregate of $8,000,000 in shares of common pursuant to this prospectus supplement and the accompanying prospectus. The purchase price for each share of common stock is $0.75. Our common stock is currently quoted on the … rmation about securities we may offer from time to time, some of which does not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined together with all documents incorporated by reference. If the description of the offering varies between this prospectus supplement and the accompanying prospectus, you should rely on the information contained in this prospectus supplement. However, if any statement in one … cialize new and improved products and services; our ability to raise capital to fund continuing operations; changes in government regulation; our ability to complete customer transactions and capital raising transactions; and other factors (including the risks contained in the sections of this prospectus supplement and the accompanying prospectus entitled “Risk Factors”) relating to our industry, our operations and results of operations and any businesses that may … y $7,220,000. We currently intend to use the net proceeds from this offering to fund the launch of our new product line, BluScience and for other general corporate purposes, including working capital.  See “Use of Proceeds” on page S-10 for more information.       Market for our common stock   Our common stock is quoted on the OTC Bulletin Board under the symbol “CDXC.”  To date, however, trading activity in our commo … ated by this prospectus supplement we will have sufficient capital resources to fund our existing plans for at least 24 months, we may require additional funds in the future, either through additional equity or debt financings or collaborative agreements or from other sources. We have no commitments to obtain such additional financing, and we may
Niagen Bioscience - Governance - Board of Directors Skip to main content Overview News Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Board of Directors Committee Composition Resources Investor FAQs Investor Email Alerts Investor Contacts Investor Docs Market Surveillance Board of Directors Governance Documents Leadership Board of Directors Committee Composition Contact Us (646) 277-1260 Stephanie Carrington (646) 277-1282 ICR, LLC --> [email protected] --> Valter Pinto (212) 89 … Reports SEC Filings End of Day Stock Quote Events & Presentations Submit Unsubscribe X Linkedin Instagram Facebook YouTube © 2026 Niagen Bioscience - All rights reserved Powered By Q4 Inc. 5.180.2.5 (opens in new window) Patents opens in new window | Privacy Policy opens in new window | California Consumer Privacy Statement opens in new window | Consumer Health Data Privacy opens in new window | Terms of Use opens in new window | Site Map opens in new window
Niagen Bioscience - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Niagen Bioscience - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Niagen Bioscience - ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment Skip to main content Overview News Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Board of Directors Committee Composition Resources Investor FAQs Investor Email Alerts Investor Contacts Investor Docs Market Surveillance News Details View All News ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Mil … Reports SEC Filings End of Day Stock Quote Events & Presentations Submit Unsubscribe X Linkedin Instagram Facebook YouTube © 2026 Niagen Bioscience - All rights reserved Powered By Q4 Inc. 5.180.2.5 (opens in new window) Patents opens in new window | Privacy Policy opens in new window | California Consumer Privacy Statement opens in new window | Consumer Health Data Privacy opens in new window | Terms of Use opens in new window | Site Map opens in new window
Instagram Instagram Log In Sign Up Close Never miss a post from niagenbioscience Sign up for Instagram to stay in the loop. Sign up Log in Tags latimes niagenbioscience • Follow More options niagenbioscience Edited • 7w Congratulations to our CEO, Robert Fried, on his nomination for the 2026 LA Times Executive Leadership Awards. With over a decade in bioscience and a track record spanning entrepreneurship and media, Rob has led Niagen Bioscience through a period of significant growth since becoming CEO in 2018—expanding the company’s reach and continuing to advance NAD+ and cellular health sci
Interview with Robert Fried, CEO of ChromaDex - Adam Mendler Meet Adam Speaking Podcast Blog Assessment Connect Meet Adam Speaking Podcast Blog Assessment Connect January 30, 2025 Embrace Innovation but Cherish Execution: Interview with Robert Fried, CEO of ChromaDex My conversation with Robert Fried, CEO of ChromaDex Adam Mendler Several years ago, I interviewed Robert Fried, CEO of ChromaDex, in an interview originally published in Thrive Global . Here is an excerpt from our conversation: Adam: How did you get here? What experiences, failures, setbacks, or challenges have been most instrumen
--> Niagen Bioscience Hits 300 Research Agreements - NAGE | BioPharma --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Conference Calendar Keep up with biotech events. IPO Upcoming & … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
Niagen Bioscience Inc. (Nasdaq: NAGE) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 115 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> WidePoint Named Single Awardee of the $3.1 Billion DHS CWMS 3.0 Contract (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historic
Niagen Bioscience Inc. (Nasdaq: NAGE) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 115 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> WidePoint Named Single Awardee of the $3.1 Billion DHS CWMS 3.0 Contract (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historic
Niagen Plus IV: A Game Changer in Wellness | Niagen Bioscience posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Lin
Niagen Bioscience to Present at 38th Annual ROTH Conference on March 18, 2026 - GeneOnline News Skip to content Advertise Inquiries | About Us | | Events Subscribe Intelligence Menu Toggle Markets & Deals Policy & Regulation Ranking & Reports Founders’ Circle Development to Market Discovery Menu Toggle R&D Frontiers Trials & Approvals CDMO & CRO Activity Public Health Oncology Insights Infection, Immunity & Vaccination Nexus Menu Toggle AI, Tech & Digital Innovation Advanced Biologics & Biosimilars Exosomes & Delivery Precision Medicines Cell, Gene
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Queen's University Assigns NAD⁺ Patent Portfolio to Niagen Bioscience | QUBIS Ltd posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si … otice that the European Patent Office will publish our Nanoparticle Formulation application this week on Jan 14, 2026. This publication secures the proprietary formulation technology essential for both our Acute (IV and Oral) and Chronic and Neuropathic (Oral) programs, extending our potential patent protection runway into 2044. These actions support the global commercial potential for SRP-001 as a best-in-class, non-opioid, non-hepatotoxic analgesic. With FDA Fast Track Desi … nd the patent lacked Written Description support. The court ruled that the 2004 application disclosed a massive "genus" of potential peptide linkers (millions of permutations) but failed to "blaze a trail" to the specific subgenus claimed in the '039 patent. The Result: Without the 2004 priority date, the patent was anticipated by intervening prior art (including public disclosures of Daiichi's own Enhertu product). A major win for Daiichi Sankyo and a critical reminder on th … re Despite Novo’s Patent On 2nd December 2025, the Delhi High Court declined to grant an interim injunction restraining Dr. Reddy’s Laboratories from manufacturing semaglutide in India for export Learn more: https://lnkd.in/gNDJEHk7 #Semaglutide #PharmaPatent #PatentLitigation #DRL #NovoNordisk #GenericMedicines #PharmaceuticalPatents #PatentExpiry #IPR #DrugManufacturing Why DRL Won the Right to Manufacture Despite Novo’s Patent khuranaandkhurana.com 8 Like Comment Share Cop … re Despite Novo’s Patent On 2nd December 2025, the Delhi High Court declined to grant an interim injunction restraining Dr. Reddy’s Laboratories from manufacturing semaglutide in India for export Learn more: https://lnkd.in/gNDJEHk7 #Semaglutide #PharmaPatent #PatentLitigation #DRL #NovoNordisk #GenericMedicines #PharmaceuticalPatents #PatentExpi
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
#bio2025 #bio2025 | Niagen Bioscience LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Pol
The Roth Conference always delivers. Thomas Rhett may have stole the show, but the Longevity and Supplementation Panel was standing room only—thank you @suzannedevkota @shahabelmi and Rob Fried from @im8health @cymbiotika and @chromadex for delivering on a spicy 🌶️ discussion about the future of our how we help people age better! #longevity #supplementation #nr #nmn #liposomal #nad #rothconference | David Vanderveen
Niagen Bioscience, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 26 Jun 2025 Niagen Bioscience, Inc. Public Company | 1999 | California, United States | 100-250 | NASDAQ: NAGE | www.niagenbioscience.com Public Company | 1999 | California, United States | 100-250 | NASDAQ: NAGE | www.niagenbioscience.com Last update 26 Jun 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Endocrinology and Metabolic Disease Other Diseases Congenital Disorders Smal … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
#hlthforward #nad #cellularhealth #cellularenergy #healthyaging | Niagen Bioscience LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s Us
Tru Niagen® | Clinically Studied NAD+ Booster for Cellular Health Prime Summer Savings: Save up to 30% for a limited time. Shop Now NAD+ skincare powered by Niagen®. Learn More . Good news: Tru Niagen now accepts HSA/FSA. Learn more . Prime Summer Savings: Save up to 30% for a limited time. Shop Now NAD+ skincare powered by Niagen®. Learn More . Good news: Tru Niagen now accepts HSA/FSA. Learn more . Skip to content Pharma-Grade Niagen HCP Pro Site Shop Explore Our Products Shop All Products Foundational Tru Niagen® 300mg Tru Niagen® 300mg Stick Packs Tru Niagen® 150mg Pro Tru Niagen Pro® 1,00 … om the NAD+ authority trusted by physicians, athletes, researchers, and a Nobel Prize-winning biochemist. 45+ Human Clinical Studies on Niagen® NR 60+ Proprietary NR Patents 500+ Published Scientific Studies 300+ Global Research Collaborations Discover the best NAD-boosting solution for you Foundational Our bestselling minimum recommended daily servings to support cellular energy and repair. Shop Now Pro Originally made for pro athletes and physicians, now available for healt … ents, and indeed, a gold standard in the industry." Roger Kornberg, Ph.D. Nobel Prize Winner in Chemistry | Mrs. George A. Winzer Professor of Medicine, Stanford | Niagen Bioscience Scientific Advisory Board Chairman "Disturbances in NAD coenzymes can leave tissues unable to repair themselves, generate energy, and perform their normal homeostatic functions. In many conditions of metabolic stress, the genes that convert NR to NAD are up-regulated, which provides unique value o
USC Aging Expert Dr. Cohen Joins Niagen Bioscience Advisory Board | NAGE Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Cryp … to Acquire Synaptics to Enable the Next Generation of Inte... DLHC DLH Contract Award Opens New Growth Channels with U.S Navy ILLR Triller Group (Nasdaq: ILLR): The Reverse Split Is Not the Story ... RKLB NASA Selects Rocket Lab to Launch Sun, Earth Sciences Missions SHPH United Dogecoin Advances Data Centre and Power Infrastructure Str... TII Titan Mining Selected by the U.S. Army to Establish First-Ever Pu... ON onsemi to Acquire Synaptics to Enable the Next Generation of I … to Acquire Synaptics to Enable the Next Generation of Inte... DLHC DLH Contract Award Opens New Growth Channels with U.S Navy ILLR Triller Group (Nasdaq: ILLR): The Reverse Split Is Not the Story ... Previous Next --> Overview Financials News SEC Filings Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board Rhea-AI Impact (Neutral) Rhea-AI Sentiment (Neutral) Tags management See more from StockTitan in Google Search and AI answers. Adds StockTitan as a pre … lude the National Institutes of Health (NIH) Director’s Transformative Research Award, the Glenn Award for Research in Biological Mechanisms of Aging, and election to both the American Association for the Advancement of Science (AAAS) and the National Academy of Inventors. Dr. Cohen expressed enthusiasm about the role, noting, "I am honored to join Niagen Bioscience's Scientific Advisory Board. The company's commitment to rigorous scientific research in the field of NAD+ and
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York Deutsch español français italiano Nederlands Login Analysis Quotes Screeners News Guides Training Londinia Platform Post an Analysis Request an analysis AI Londinia analysis Londinia Opportunities All Trading Opportunities Europe Stocks U.S. Stocks FX/Indices Cryptocurrencies Technical analyses All technical analyses Stocks Indices Forex Commodities Cryptocurrencies Futures AI analyses Need technical analysis? Request an analysis from members Request an analysis from Londinia Ranking Financial instrume … en is backed by the highest scientific and quality standards, including a Nobel Prize winner, 35+ human clinical studies, 400+ published scientific studies, and has been accepted by the world’s most rigorous regulatory bodies. All Tru Niagen products are third-party certified, with Tru Niagen Pro 1,000mg and Tru Niagen Stick Packs NSF Certified for Sport , ensuring their safety, quality, and integrity for elite athletes and fitness enthusiasts alike. Niagen IV represents a si
ChromaDex, Inc. And Healthy Directions Enter Into NIAGEN™ Supply Agreement - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opini … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business ChromaDex, Inc. And Healthy Directions Enter Into NIAGEN™ Supply Agreement September 11, 2014 | 8 min read Twitter LinkedIn Facebook Email Print IRVINE, Calif. , Sept. 11, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides prop … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Niagen Bioscience Colorado Jobs + Careers | Built In Colorado Colorado Global Tech Hub BuiltIn.com is the global destination for tech professionals. builtin.com Popular Tech Hubs United States Austin Boston Chicago Colorado Los Angeles New York City Seattle San Francisco Australia Sydney Melbourne Canada Calgary Montreal Ottawa Quebec Toronto Vancouver India Bengaluru Chennai Delhi Hyderabad Kolkata Mumbai Pune Ireland Dublin Singapore Singapore United Kingdom London Cambridge Manchester Birmingham Bristol Companies Jobs Articles Can't find your company? Create a company profile. View All
ChromaDex Corp. (Form: 10-K, Received: 03/06/2024 16:02:47) 0001386570falseFY2023http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613MemberP3Y0.33330.33330.33330.33330.333300013865702023-01-012023-12-3100013865702023-06-30iso4217:USD00013865702024-03-04xbrli:shares00013865702023-12-3100013865702022-12-310001386570us-gaap:RelatedPartyMember2023-12-310001386570us-gaap:RelatedPartyMember2022-12-310001386570us-gaap:NonrelatedPartyMember2023-12-310001386570us-gaap:NonrelatedPartyMember2022-12-31iso4217:USDxbrli:shares00013865702022-01-012022-12-310001386570us-gaap:CommonStockMember2021-12-3 … eding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No • whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “accelerated filer,” “large accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated … -party party suppliers for certain raw materials; inability to raise capital to fund continuing operations; changes in government regulation; the ability to complete customer transactions and capital raising transactions, and other factors (including the risks contained in Item 1A of this Form 10-K under the heading “Risk Factors”) relating to our industry, our operations and results of operations and any businesses that may be acquired by us. Should one or more o … ve our Tru Niagen® products through ongoing exploration, discovery and the application of patented technologies. We believe that the Tru Niagen® brand is associated with scientific rigor and a dedication to enhancing consumer health by safely elevating NAD+ levels, thereby facilitating a healthier aging process. Our primary objective is to amplify global awareness of the Tru Niagen® brand through comprehensive marketing strategies, strategic partnerships and ex … to our customers. We aim to develop these proprietary ingredients ourselves and grant licenses to external companies for their commercialization. The following table sets forth our existing patents and those to which we have licensed rights: Patent Number Title Filling Date Issued Date Expires Licensor 7,776,326 Methods and compositions for treat
Niagen Bioscience | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Niagen Bioscience Website: Niagen Bioscience Business Area(s) Natural Products Nutritional Supplements Description Develops ways to increase NAD+ for health. Career Page(s) Careers Company Location(s) 10900 Wilshire Blvd Suite 600 Los Angeles , CA 90024 United States 1735 Flight Way Suite 200